Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

As part of "heart health month," we're looking at lipoprotein (a). For decades, doctors have encouraged patients to monitor their cholesterol levels, with studies showing that heart disease risk ...

Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular ...

A nearly 30-year study shows a strong long-term association between very high lipoprotein(a) levels and cardiovascular ...

Find out how lipoprotein(a) screening identifies women at long term cardiovascular risk and supports earlier prevention ...

A new study finds that elevated levels of Lp(a) may increase the risk of death from cardiovascular disease in some patie ...

Researchers have conducted the first human trials of a new drug, lepodisiran, and found that a single injection reduced lipoprotein(a) – a ‘bad’ cholesterol with a genetic basis – to undetectable ...

Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

The evidence implicating high levels of lipoprotein(a), or Lp(a), as a risk predictor for heart attack, stroke, and other cardiovascular conditions has outpaced the science of what to do about the ...